The FDA has granted 510(k) clearance to Medtronic for its MiniMed “Go Smart” multiple daily injection system — the first ...
The bispecific antibody is used to treat patients with relapsed or refractory multiple myeloma (R/R MM) who have achieved and maintained a complete response for at least 6 months; this approval allows ...
NEW YORK, NY / ACCESS Newswire / August 21, 2025 / Protagenic Therapeutics, Inc. (PTIX), a biopharmaceutical company developing novel neuro-active peptide therapies, today announced completion of ...
The new biweekly dosing regimen for Tecvayli is intended for patients with RRMM who have achieved and maintained a complete response or better for a minimum of 6 months. The Food and Drug ...
"TECVAYLI is the only BCMA-targeted immune-based therapy with weight-based dosing. Today's approval of biweekly dosing for eligible patients will further enable clinicians to meet the individual needs ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and safety in diverse patient populations. The MUSETTE trial confirmed that the ...
SHELTON, CT / ACCESSWIRE / January 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback